The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Welcome Woody............!
I have to ask though......... TO..........the acronym.......?
All the best (lost on me bud........... :()
Welcome Woody, great post.
I’ve been following and backing MWG and SKIN for sometime (now DeepVerge / DVRG). They’re among an elite group of AIM listed companies working to help solve the Covid 19 crisis. The main companies all have a lot in common, in that they’ve all been making recent losses but have seen their share prices rise significantly this year... though DVRG still remains well below the average in terms of Mcap, despite possibly having the best solution!
1. Novacyt
Mcap £843M
TO £13.08M
LOSS £6.56M
2. Avacta
Mcap £445M
TO £5.51M
LOSS £15.61M
3. Synairgen
Mcap £292M
TO £ N/A
LOSS £3.88M
4. Open Orphan
Mcap £176M
TO £3.84M
LOSS £6.54M
5. Omega Diagnostics
Mcap £175M
TO £9.82M
LOSS £6.83M
6. 4D Pharma
Mcap £175M
TO £.21M
LOSS £24M
7. DeepVerge
Mcap £37M
TO £.82M
LOSS £2.3M
On average the companies have a market cap of £306M verses DVRG £37M, average turnover of £4.75M which is not far off the forecasted TO for 2020 for DVRG. Average loss of 9.38M, over 4 times DVRGs.
This alone surly makes this an incredible buying opportunity? The company has so many exciting developments even without any Covid involvement. If they get through the level three lab testing (and it seems they should), they will have significant first mover advantage for a complete Covid 19 solution to help unlock the world and get all our lives back to normal.
The global market for testing based on just half the world being tested just once a week, is estimated to be a Trillion dollars, annually! There is no vaccine that will make this virus go away quickly, so testing is the key, and we will need good testing capability for evermore as we have seen the deviating effects a virus causes, even if a vaccine is developed.
It seems to be a case of either paying 30 to 40 something pence now, or possibly several pounds when the Microtox BT breathalyzer hits the market! This has to be one of the most exciting and undervalued companies I have ever seen and I’m very pleased to be a part of their exciting journey!